Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Irinotecan. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TOP1 known ✓ | P11387 | 6/20 | 0.78 |
| ▸ | GLA | P06280 | 2/20 | 1.00 |
| ▸ | GAA | P10253 | 2/20 | 1.00 |
| ▸ | SLC22A2 | O15244 | 1/20 | 1.00 |
| ▸ | SLC22A1 | O15245 | 1/20 | 1.00 |
| ▸ | SLC22A3 | O75751 | 1/20 | 1.00 |
| ▸ | MMP1 | P03956 | 1/20 | 1.00 |
| ▸ | CHRM4 | P08173 | 1/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 1/20 | 1.00 |
| ▸ | ADRA2C | P18825 | 1/20 | 1.00 |
| ▸ | ACHE | P22303 | 1/20 | 1.00 |
| ▸ | SLC47A2 | Q86VL8 | 1/20 | 1.00 |
| ▸ | SLC47A1 | Q96FL8 | 1/20 | 1.00 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.99 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.99 |
| ▸ | LMNA | P02545 | 1/20 | 0.99 |
| ▸ | HPGD | P15428 | 1/20 | 0.99 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.99 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.99 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.97 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Irinotecan SCHEMBL29367581 | 1.00 | GLA (1.00) | GLAGAASLC22A2SLC22A1SLC22A3 | |
| Irinotecan SCHEMBL131381 | 1.00 | GLA (1.00) | GLAGAASLC22A2SLC22A1SLC22A3 | |
| Irinotecan SCHEMBL29356918 | 1.00 | GLA (1.00) | GLAGAASLC22A2SLC22A1SLC22A3 | |
| Irinotecan SCHEMBL4034 | 1.00 | GLA (1.00) | GLAGAASLC22A2SLC22A1SLC22A3 | |
| Irinotecan SCHEMBL13420262 | 1.00 | GLA (1.00) | GLAGAASLC22A2SLC22A1SLC22A3 | |
| Irinotecan SCHEMBL12313065 | 1.00 | GLA (1.00) | GLAGAASLC22A2SLC22A1SLC22A3 | |
| Irinotecan SCHEMBL1501486 | 0.99 | GLA (0.99) | GLAGAASLC22A2SLC22A1SLC22A3 | |
| Irinotecan SCHEMBL4164613 | 0.99 | GLA (0.99) | GLAGAASLC22A2SLC22A1SLC22A3 | |
| Irinotecan SCHEMBL5693425 | 0.99 | PAX8 (0.99) | GLAGAASLC22A2SLC22A1SLC22A3 | |
| Irinotecan SCHEMBL4450369 | 0.99 | GLA (1.00) | GLAGAASLC22A2SLC22A1SLC22A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210252160-A1 | COMPOUNDS, COMPOSITIONS, METHODS, AND USES FOR TREATING CANCER AND IMMUNOLOGICAL DISORDERS | IL-2RX | 2021-08-19 | — | — | US | disclosed |
| US-20210205456-A1 | TARGETED LIPOSOMES | GEORGETOWN UNIVERSITY | 2021-07-08 | — | — | US | disclosed |
| US-20170312278-A1 | METHODS FOR TREATING CANCER USING TOR KINASE INHIBITOR COMBINATION THERAPY COMPRISING ADMINISTERING SUBSTITUTED PYRAZINO[2,3-b]PYRAZINES | SIGNAL PHARM LLC (US) | 2017-11-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210252160-A1 | COMPOUNDS, COMPOSITIONS, METHODS, AND USES FOR TREATING CANCER AND IMMUNOLOGICAL DISORDERS | TNFRSF9, EGFR, NGFR | TOP1 4164/4885GLA 2648/4885GAA 858/4885 |
| US-20210205456-A1 | TARGETED LIPOSOMES | MEN1, RB1, CD47 | TOP1 144/4885GLA 1673/4885GAA 1068/4885 |
| US-20170312278-A1 | METHODS FOR TREATING CANCER USING TOR KINASE INHIBITOR COMBINATION THERAPY COMPRISING ADMINISTERING SUBSTITUTED PYRAZINO[2,3-b]PYRAZINES | MTOR, ULK2, TTK | TOP1 509/4885GLA 3077/4885GAA 2000/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.